PURPOSE: To evaluate the in vivo effect of adding gefitinib to preoperative chemotherapy on the EGFR-dependent p42/44 MAPK in operable breast cancer (BC) patients. Secondary aims: to evaluate EGFR, (p)-EGFR, Ki67, apoptotic index (TUNEL test) and VEGFR2 expression from baseline to surgery, percentage of pathologic complete response (pCR), and toxicity. PATIENTS AND METHODS: 90 patients with stage II-IIIA BC have been randomized to receive epirubicin 90 mg/sqm and paclitaxel 175 mg/sqm on day 1 plus: gefitinib 250 mg daily from day 5 to 16 (Arm A, intermittent), gefitinib 250 mg daily from day 1 to 21 (Arm B, continuous), or placebo (Arm C). Treatment plan: 4 courses every 3 weeks, followed by surgery. RESULTS: After preoperative therapy, 86/90 patients underwent surgery; 46 patients (51%) received breast conservative surgery. A pCR was observed in 4 patients. No significant differences in the expression of p42/44 MAPK, EGFR, (p)-EGFR, VEGFR2, proliferation index and apoptosis were observed comparing the combined Arms A + B vs C, and comparing Arm A vs B. Hematologic toxicities were not significantly different comparing Arms A + B vs Arm C, and comparing Arm A vs B. Significantly higher skin and mucosal toxicities were observed when comparing the two gefitinib Arms (A + B) vs Arm C (32% vs 9.6%, P = 0.018; 57% vs 29%, P = 0.009 respectively), while no significant differences were observed comparing Arm A vs B. CONCLUSION: Adding gefitinib to chemotherapy did not result in different effects on the EGFR-dependent pathway, proliferation, apoptosis and VEGFR2 expression as compared to placebo, while enhancing skin and mucosal toxicity. The two schedules of gefitinib (intermittent vs continuous) did not result in different biologic effects.

Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer / Guarneri, Valentina; Frassoldati, A.; Ficarra, G.; Puglisi, F.; Andreetta, C.; Michelotti, A.; Cresti, N.; Boni, C.; Bisagni, G.; Berardi, R.; Battelli, N.; Santoro, A.; Banna, G.; Bottini, A.; DI BLASIO, B.; Maiorana, Antonino; Piacentini, Federico; Giovannelli, Simona; Jovic, Gordana; Conte, Pierfranco. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - STAMPA. - 110:1(2008), pp. 127-134. [10.1007/s10549-007-9688-3]

Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer.

GUARNERI, Valentina;A. FRASSOLDATI;MAIORANA, Antonino;PIACENTINI, Federico;GIOVANNELLI, Simona;JOVIC, Gordana;CONTE, Pierfranco
2008

Abstract

PURPOSE: To evaluate the in vivo effect of adding gefitinib to preoperative chemotherapy on the EGFR-dependent p42/44 MAPK in operable breast cancer (BC) patients. Secondary aims: to evaluate EGFR, (p)-EGFR, Ki67, apoptotic index (TUNEL test) and VEGFR2 expression from baseline to surgery, percentage of pathologic complete response (pCR), and toxicity. PATIENTS AND METHODS: 90 patients with stage II-IIIA BC have been randomized to receive epirubicin 90 mg/sqm and paclitaxel 175 mg/sqm on day 1 plus: gefitinib 250 mg daily from day 5 to 16 (Arm A, intermittent), gefitinib 250 mg daily from day 1 to 21 (Arm B, continuous), or placebo (Arm C). Treatment plan: 4 courses every 3 weeks, followed by surgery. RESULTS: After preoperative therapy, 86/90 patients underwent surgery; 46 patients (51%) received breast conservative surgery. A pCR was observed in 4 patients. No significant differences in the expression of p42/44 MAPK, EGFR, (p)-EGFR, VEGFR2, proliferation index and apoptosis were observed comparing the combined Arms A + B vs C, and comparing Arm A vs B. Hematologic toxicities were not significantly different comparing Arms A + B vs Arm C, and comparing Arm A vs B. Significantly higher skin and mucosal toxicities were observed when comparing the two gefitinib Arms (A + B) vs Arm C (32% vs 9.6%, P = 0.018; 57% vs 29%, P = 0.009 respectively), while no significant differences were observed comparing Arm A vs B. CONCLUSION: Adding gefitinib to chemotherapy did not result in different effects on the EGFR-dependent pathway, proliferation, apoptosis and VEGFR2 expression as compared to placebo, while enhancing skin and mucosal toxicity. The two schedules of gefitinib (intermittent vs continuous) did not result in different biologic effects.
9-ago-2007
110
1
127
134
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer / Guarneri, Valentina; Frassoldati, A.; Ficarra, G.; Puglisi, F.; Andreetta, C.; Michelotti, A.; Cresti, N.; Boni, C.; Bisagni, G.; Berardi, R.; Battelli, N.; Santoro, A.; Banna, G.; Bottini, A.; DI BLASIO, B.; Maiorana, Antonino; Piacentini, Federico; Giovannelli, Simona; Jovic, Gordana; Conte, Pierfranco. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - STAMPA. - 110:1(2008), pp. 127-134. [10.1007/s10549-007-9688-3]
Guarneri, Valentina; Frassoldati, A.; Ficarra, G.; Puglisi, F.; Andreetta, C.; Michelotti, A.; Cresti, N.; Boni, C.; Bisagni, G.; Berardi, R.; Battelli, N.; Santoro, A.; Banna, G.; Bottini, A.; DI BLASIO, B.; Maiorana, Antonino; Piacentini, Federico; Giovannelli, Simona; Jovic, Gordana; Conte, Pierfranco
File in questo prodotto:
File Dimensione Formato  
GIOB 2007.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 236.26 kB
Formato Adobe PDF
236.26 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/310507
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 21
social impact